TargetAD: A network approach to repurpose drugs for Alzheimer's disease
Official title: TargetAD: A systems multi-omics approach to drug repositioning in Alzheimer's disease
Funded at Weill Medical Coll of Cornell Univ · NIH-11600904 · Data updated 2026-11-12
A research project is building a big, interconnected map of biological data to find existing drugs that could help people with Alzheimer’s disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2021 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $140,246 |
| NIH project number | 3R01AG069901-05S1 |
| Project ID | NIH-11600904 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with late-onset Alzheimer’s disease or those at risk who may be eligible for future trials given the identified drugs
✕Less likely to help
People whose disease does not align with the identified targets or who are not candidates for the proposed drug mechanisms may not benefit
What this research studies
This project uses a multi-omics, network-based framework to connect genetic, expression, metabolic, and protein data with known drug targets and signatures. By integrating data across regulatory layers and tissue-specific contexts, the team aims to identify existing drugs that may be repurposed to modify disease pathways in late-onset Alzheimer’s disease. The work combines large-scale data analysis with drug-target information to propose candidate therapies for future testing. The goal is to streamline the discovery process so patients may benefit from treatments faster than with traditional new-drug development.
Why it matters
Potential benefit: If successful, the project could point to approved drugs that may slow or alter the progression of Alzheimer’s disease.
How similar studies have gone: Previous multi-omics and network-based drug repositioning efforts have shown potential but require validation in clinical settings
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Krumsiek, Jan — Weill Medical Coll of Cornell Univ
- Study coordinator: Krumsiek, Jan
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.